CD8A and neoplasm: There was reported synergy between PD-1 blockade and CD27 stimulation for CD8+ T-cell driven anti-tumor immunity [62], indicating the therapeutic potential of CD27 in neoadjuvant PD-1 blockade in early-stage NSCLC [63].